Three companies jointly conduct clinical trials of antibody-linked drug enfortumab vedotin and Keytruda to treat urinary skin cancer
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, Seattle Genetics and Astellas announced a partnership agreement with Mercadon to jointly conduct a clinicaltrial(http://for the treatment of pre-local advanced or metastatic urinary tract cancer in the antibody-bindingdrug(http://(ADC) enfortumab vedotin and Keytrudathreecompanies,(http://will fund a globally registered Phase III study, led by Seattle Genetics, which is currently in communication with regulators on pilot design and is expected to launch in the first half of 2020enfortumab vedotin has filed a listing application with theFDA(http://for localized advanced or metastatic urinary tract cancer that has received PD-1/L1 inhibitors and new assisted chemotherapy/assisted chemotherapy containing platinum, and is currently under FDA review, with a PDUFA date of March 15 next yearEnfortumab vedotin uses Seattle Genetics' proprietary connection technology to connect microtube destroyer MMAE to anti-Nectin-4 monoclonal antibodies Enfortumab vedotin can target Nectin-4, a cell adhesion molecule expressed on a variety of solid tumors
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
